Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 1708-1717, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (64)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Orfao, A.
Right arrow Articles by San Miguel, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orfao, A.
Right arrow Articles by San Miguel, J. F.
Related Collections
Right arrow Hematology
(Clinical Chemistry. 1999;45:1708-1717.)
© 1999 American Association for Clinical Chemistry, Inc.

Articles

Clinically Useful Information Provided by the Flow Cytometric Immunophenotyping of Hematological Malignancies: Current Status and Future Directions

Alberto Orfao1,a, Gerd Schmitz2, Bruno Brando3, Alejandro Ruiz-Arguelles4, Giuseppe Basso5, Raul Braylan6, Gregor Rothe2, Francis Lacombe7, Francesco Lanza8, Stefano Papa9, Paulo Lucio10, Jesus F. San Miguel1 and for the Standardization Committee on Clinical Flow Cytometry of the International Federation of Clinical Chemistry

1 Department of Medicine and Centro de Investigaciones del Cancer, Universidad de Salamanca, 37007 Salamanca, Spain.

2 Department of Laboratory Medicine, University of Regensburg, D-93053 Regensburg, Germany.

3 Renal Transplant Unit, Niguarda-Ca' Granda Hospital, 20162 Milan, Italy.

4 Laboratorios Clinicos de Puebla, Puebla 72530, Mexico.

5 Clinica Pediatrica, 10126 Torino, Italy.

6 Department of Pathology, University of Florida, Gainesville, FL 32610.

7 Laboratoire d'Hematologie, Hopital Haut-Leveque, 33608 Pessac, France.

8 Institute of Hematology, Ospedale S. Anna, 44100 Ferrara, Italy.

9 Istituto di Scienze Morfologiche, Universita degli Study di Urbino, 61029 Urbino, Italy.

10 Serviço de Hematologia, Instituto Portugues de Oncologia, 1093 Lisbon, Portugal.
a Address correspondence to this author at: Servicio General de Citometria, Laboratorio de Hematologia, Hospital Universitario, Paseo San Vicente s/n, 37007 Salamanca, Spain. Fax 34-23-294624; e-mail orfao{at}gugu.usal.es

Background: At present, immunophenotyping of hematological malignancies represents one of the most relevant clinical applications of flow cytometry. In recent years, its use has extended from clinical research to diagnostic laboratories. The aim of this report is to critically review the type of information provided by the flow cytometric immunophenotyping of hematological malignancies and its clinical impact as well as to highlight its potential future applications.

Methods: The currently available information, including that provided by different international consensus groups on the phenotypic characterization of hematologic malignancies, was reviewed. Additionally, recent reports on the immunophenotypic analysis of hematological malignancies published in hematology, oncology, pathology, immunology, and cell biology journals were also analyzed.

Results: A careful review of the literature showed that in spite of the well-established utility of immunophenotyping for the diagnosis, classification, prognostic stratification, and monitoring of hematological malignancies, only a small part of the information on the immunophenotypic characteristics of pathological hemopoietic cells has been used routinely. Specific and sensitive identification of neoplastic cells and their accurate enumeration and phenotypic characterization represent the major aims of these procedures. Similarities between leukemic and healthy cells allow the establishment of the lineage and maturation stage of the pathologic cells, this information being of great utility for the diagnosis, classification, and prognostic evaluation of different subtypes of hematological malignancies. On the other hand, the phenotypic aberrations displayed by leukemic cells could allow the selection of cases carrying specific genetic abnormalities in which further confirmatory molecular studies will be performed.

Conclusions: The information provided by the flow cytometric immunophenotyping of hematological malignancies is of great clinical utility, with a major challenge for the near future being the standardization of technical procedures, data interpretation, and reporting.




The following articles in journals at HighWire Press have cited this article:


Home page
 Am J Clin PatholHome page
A. Al-Mawali, D. Gillis, and I. Lewis
The Role of Multiparameter Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia
Am J Clin Pathol, January 1, 2009; 131(1): 16 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
I. Matushansky, E. Hernando, N. D. Socci, T. Matos, J. Mills, M. A. Edgar, G. K. Schwartz, S. Singer, C. Cordon-Cardo, and R. G. Maki
A Developmental Model of Sarcomagenesis Defines a Differentiation-Based Classification for Liposarcomas
Am. J. Pathol., April 1, 2008; 172(4): 1069 - 1080.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Lima, J. Almeida, A. G. Montero, M. d. A. Teixeira, M. L. Queiros, A. H. Santos, A. Balanzategui, A. Estevinho, M. d. C. Alguero, P. Barcena, et al.
Clinicobiological, Immunophenotypic, and Molecular Characteristics of Monoclonal CD56-/+dim Chronic Natural Killer Cell Large Granular Lymphocytosis
Am. J. Pathol., October 1, 2004; 165(4): 1117 - 1127.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. F. San Miguel, M. B. Vidriales, C. Lopez-Berges, J. Diaz-Mediavilla, N. Gutierrez, C. Canizo, F. Ramos, M. J. Calmuntia, J. J. Perez, M. Gonzalez, et al.
Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification
Blood, September 15, 2001; 98(6): 1746 - 1751.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Brown and C. Wittwer
Flow Cytometry: Principles and Clinical Applications in Hematology
Clin. Chem., August 1, 2000; 46(8): 1221 - 1229.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.